[
  {
    "element_id": "dc2a82517efea79282ff25605fb9d8b8",
    "page_number": 6,
    "caption": "Table 1 Participant characteristics at baseline",
    "table_text": "hydrocortisone or control sone and control Hydrocortisone (n = 536) Control (n = 122) Hydrocortisone (n = 339) Control (n = 116) Shock, influenza 25 (4.7) 4 (3.3) 19 (5.6) 3 (2.6) Shock, no influenza 238 (44.4) 54 (44.3) 145 (42.8) 54 (46.6) No shock, influenza 20 (3.7) 5 (4.1) 11 (3.2) 5 (4.3) No shock, no influenza 253 (47.2) 59 (48.4) 164 (48.4) 54 (46.6) 62.5 (52–73) 58.5 (48–68) 63 (53–73) 58 (47.8–68) 204 (38.1) 54 (44.3) 125 (36.9) 51 (44) Asian 19/322 (5.9) 2/82 (2.4) 18/207 (8.7) 2/80 (2.5) Black 3/322 (0.9) 0/82 (0) 0/207 (0) 0/80 (0) Mixed 0/322 (0) 0/82 (0) 0/207 (0) 0/80 (0) White 235/322 (73) 52/82 (63.4) 145/207 (70) 52/80 (65) Other 65/322 (20.2) 28/82 (34.1) 44/207 (21.3) 26/80 (32.5) 27.7 (23.8–33.1) (n = 487) 27.7 (23.5–35.6) (n = 113) 27.2 (23.7–32.8) (n = 312) 27.7 (23.5–35.7) (n = 107) 18 (13–24) (n = 511) 18 (13–22) (n = 119) 19 (14–24) (n = 323) 18 (13–22) (n = 114) 3 (2–4) (n = 532) 3 (2–4) 3 (2–4) (n = 336) 3 (2–4) Diabetes 161/532 (30.3) 27 (22.1) 101/336 (30.1) 26 (22.4) Respiratory disease 183/533 (34.3) 42 (34.4) 120/337 (35.6) 41 (35.3) Kidney disease 63/439 (14.4) 20/90 (22.2) 36/260 (13.8) 20/86 (23.3) Severe cardiovascular disease 44/533 (8.3) 9 (7.4) 29/337 (8.6) 9 (7.8) Any immunosuppressive condition 35/532 (6.6) 6 (4.9) 21/336 (6.2) 5 (4.3) From hospital admission, days 0.8 (0.5–1.1) 0.7 (0.4–1) 0.8 (0.4–1.1) 0.7 (0.4–1) From ICU admission, hours 8.2 (2.8–16.1) 7.4 (2.4–13.5) 7.4 (2.6–15.3) 7.1 (2.3–13.2) Invasive mechanical ventilation 213 (39.7) 46 (37.7) 139 (41) 44 (37.9) Noninvasive ventilation only 76 (14.2) 21 (17.2) 39 (11.5) 21 (18.1) High-flow nasal cannula 206 (38.4) 39/118 (33.1) 134 (39.5) 35/112 (31.2) None/supplemental oxygen 41 (7.6) 12/118 (10.2) 27 (8) 12/112 (10.7) PaO2/FiO2, median (IQR) 156 (114–214) (n = 457) 168 (127.5–235.5) (n = 107) 155 (113–215) (n = 281) 167 (127–234) (n = 101) Extended cardiovascular SOFA score, median (IQR)f 2 (0–3) (n = 522) 1 (0–3) (n = 109) 3 (0–3) (n = 326) 1 (0–3) (n = 103) Lactate, mmol/L 1.6 (1.1–2.3) (n = 514) 1.5 (1–2.3) 1.7 (1.2–2.4) (n = 326) 1.6 (1–2.3) Creatinine, mg/dL 1.1 (0.8–1.5) (n = 526) 1.1 (0.8–1.8) (n = 120) 1.1 (0.8–1.6) (n = 334) 1.2 (0.8–1.8) (n = 114) eGFR, min/min/1.73 m2 73.4 (45.6–100.2) (n = 526) 68.5 (35.7–99.7) (n = 120) 70.4 (46–97) (n = 334) 67.5 (36.5–100) (n = 114) No pathogen isolated, n/total (%) 278/532 (52.2) 71/119 (59.7) 166/336 (49.4) 65/113 (57.5) Bacterial pathogen isolated, n/total 221/532 (41.5) 44/119 (37) 145/336 (43.2) 44/113 (38.9) (%) Streptococcus pneumoniae 110/532 (20.7) 24/119 (20.2) 66/336 (19.6) 23/113 (20.4) Atypical bacterial pathogenh 54/528 (10.2) 8/119 (6.7) 38/335 (11.3) 8/113 (7.1)",
    "table_html": "<pre>hydrocortisone or control sone and control Hydrocortisone (n = 536) Control (n = 122) Hydrocortisone (n = 339) Control (n = 116) Shock, influenza 25 (4.7) 4 (3.3) 19 (5.6) 3 (2.6) Shock, no influenza 238 (44.4) 54 (44.3) 145 (42.8) 54 (46.6) No shock, influenza 20 (3.7) 5 (4.1) 11 (3.2) 5 (4.3) No shock, no influenza 253 (47.2) 59 (48.4) 164 (48.4) 54 (46.6) 62.5 (52–73) 58.5 (48–68) 63 (53–73) 58 (47.8–68) 204 (38.1) 54 (44.3) 125 (36.9) 51 (44) Asian 19/322 (5.9) 2/82 (2.4) 18/207 (8.7) 2/80 (2.5) Black 3/322 (0.9) 0/82 (0) 0/207 (0) 0/80 (0) Mixed 0/322 (0) 0/82 (0) 0/207 (0) 0/80 (0) White 235/322 (73) 52/82 (63.4) 145/207 (70) 52/80 (65) Other 65/322 (20.2) 28/82 (34.1) 44/207 (21.3) 26/80 (32.5) 27.7 (23.8–33.1) (n = 487) 27.7 (23.5–35.6) (n = 113) 27.2 (23.7–32.8) (n = 312) 27.7 (23.5–35.7) (n = 107) 18 (13–24) (n = 511) 18 (13–22) (n = 119) 19 (14–24) (n = 323) 18 (13–22) (n = 114) 3 (2–4) (n = 532) 3 (2–4) 3 (2–4) (n = 336) 3 (2–4) Diabetes 161/532 (30.3) 27 (22.1) 101/336 (30.1) 26 (22.4) Respiratory disease 183/533 (34.3) 42 (34.4) 120/337 (35.6) 41 (35.3) Kidney disease 63/439 (14.4) 20/90 (22.2) 36/260 (13.8) 20/86 (23.3) Severe cardiovascular disease 44/533 (8.3) 9 (7.4) 29/337 (8.6) 9 (7.8) Any immunosuppressive condition 35/532 (6.6) 6 (4.9) 21/336 (6.2) 5 (4.3) From hospital admission, days 0.8 (0.5–1.1) 0.7 (0.4–1) 0.8 (0.4–1.1) 0.7 (0.4–1) From ICU admission, hours 8.2 (2.8–16.1) 7.4 (2.4–13.5) 7.4 (2.6–15.3) 7.1 (2.3–13.2) Invasive mechanical ventilation 213 (39.7) 46 (37.7) 139 (41) 44 (37.9) Noninvasive ventilation only 76 (14.2) 21 (17.2) 39 (11.5) 21 (18.1) High-flow nasal cannula 206 (38.4) 39/118 (33.1) 134 (39.5) 35/112 (31.2) None/supplemental oxygen 41 (7.6) 12/118 (10.2) 27 (8) 12/112 (10.7) PaO2/FiO2, median (IQR) 156 (114–214) (n = 457) 168 (127.5–235.5) (n = 107) 155 (113–215) (n = 281) 167 (127–234) (n = 101) Extended cardiovascular SOFA score, median (IQR)f 2 (0–3) (n = 522) 1 (0–3) (n = 109) 3 (0–3) (n = 326) 1 (0–3) (n = 103) Lactate, mmol/L 1.6 (1.1–2.3) (n = 514) 1.5 (1–2.3) 1.7 (1.2–2.4) (n = 326) 1.6 (1–2.3) Creatinine, mg/dL 1.1 (0.8–1.5) (n = 526) 1.1 (0.8–1.8) (n = 120) 1.1 (0.8–1.6) (n = 334) 1.2 (0.8–1.8) (n = 114) eGFR, min/min/1.73 m2 73.4 (45.6–100.2) (n = 526) 68.5 (35.7–99.7) (n = 120) 70.4 (46–97) (n = 334) 67.5 (36.5–100) (n = 114) No pathogen isolated, n/total (%) 278/532 (52.2) 71/119 (59.7) 166/336 (49.4) 65/113 (57.5) Bacterial pathogen isolated, n/total 221/532 (41.5) 44/119 (37) 145/336 (43.2) 44/113 (38.9) (%) Streptococcus pneumoniae 110/532 (20.7) 24/119 (20.2) 66/336 (19.6) 23/113 (20.4) Atypical bacterial pathogenh 54/528 (10.2) 8/119 (6.7) 38/335 (11.3) 8/113 (7.1)</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_1.html",
    "associated_text": [
      "All patients randomized to",
      "Subset randomized at sites offering hydrocorti",
      "Strata*, n (%)",
      "Age in years, median (IQR)",
      "Female sex, n (%)",
      "Race/ethnicitya, n/total (%)"
    ]
  },
  {
    "element_id": "971134d38d3691f2bbe7bc04bf6f0007",
    "page_number": 7,
    "caption": "Table 1 (continued)",
    "table_text": "All patients randomized to hydrocortisone or control sone and control Hydrocortisone (n = 536) Control (n = 122) Hydrocortisone (n = 339) Control (n = 116) Continent, n (%) Asia 18 (3.4) 0 (0) 1 (0.3) 0 (0) Australia 304 (56.7) 73 (59.8) 197 (58.1) 71 (61.2) Europe 178 (33.2) 38 (31.1) 105 (31) 36 (31) North America 36 (6.7) 11 (9) 36 (10.6) 9 (7.8)",
    "table_html": "<pre>All patients randomized to hydrocortisone or control sone and control Hydrocortisone (n = 536) Control (n = 122) Hydrocortisone (n = 339) Control (n = 116) Continent, n (%) Asia 18 (3.4) 0 (0) 1 (0.3) 0 (0) Australia 304 (56.7) 73 (59.8) 197 (58.1) 71 (61.2) Europe 178 (33.2) 38 (31.1) 105 (31) 36 (31) North America 36 (6.7) 11 (9) 36 (10.6) 9 (7.8)</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_2.html",
    "associated_text": [
      "0/336 (0)",
      "1/112 (0.9)",
      "Subset randomized at sites offering hydrocorti",
      "Percentages may not sum to 100 because of rounding. Within the control arm, six patients were randomized in sites offering shock dependent hydrocortisone, but not fixed duration hydrocortisone",
      "SD standard deviation, IQR interquartile range, ICU intensive care unit, FiO2 fraction of inspired oxygen, Pao2 arterial partial pressure of oxygen, eGFR estimated glomerular filtration rate, SARS CoV 2 severe acute respiratory syndrome coronavirus 2",
      "Strata were determined at enrollment. Patients were classified as ‘influenza’ if influenza was confirmed or suspected"
    ]
  },
  {
    "element_id": "a42e4e2527a3381cb91358929e958104",
    "page_number": 9,
    "caption": "Table 2 Primary outcome and sensitivity analyses in the full dataset",
    "table_text": "90-day mortality Hydrocortisone (n = 536) Control (n = 122) Primary analysis using the full model Vasopressor- Yes Yes No No Yes Yes No No dependent shock Influenza Yes No Yes No Yes No Yes No # Patients evalu- 25/25 233/238 16/20 247/253 4/4 54/54 5/5 59/59 ated/total # Deaths n (%) 4 (16) 38 (16.3) 2 (12.5) 34 (13.8) 0 (0) 7 (13) 1 (20) 4 (6.8) Median adjusted 1.52 (0.69–3.56) 1.53 (0.76–3.29) 1.62 (0.73–3.84) 1.63 (0.80–3.59) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) OR (95% CrI) Mean adjusted OR 1.67 (0.75) 1.65 (0.66) 1.79 (0.83) 1.78 (0.73) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) (SD) Probability of 15.7 12.1 12.6 9.2 – – – – superiority, % Probability of 84.3 87.9 87.4 90.8 – – – – harm, % Probability 7.1 4.4 5.3 3.3 – – – – of > 20% reduc- tion in odds of",
    "table_html": "<pre>90-day mortality Hydrocortisone (n = 536) Control (n = 122) Primary analysis using the full model Vasopressor- Yes Yes No No Yes Yes No No dependent shock Influenza Yes No Yes No Yes No Yes No # Patients evalu- 25/25 233/238 16/20 247/253 4/4 54/54 5/5 59/59 ated/total # Deaths n (%) 4 (16) 38 (16.3) 2 (12.5) 34 (13.8) 0 (0) 7 (13) 1 (20) 4 (6.8) Median adjusted 1.52 (0.69–3.56) 1.53 (0.76–3.29) 1.62 (0.73–3.84) 1.63 (0.80–3.59) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) OR (95% CrI) Mean adjusted OR 1.67 (0.75) 1.65 (0.66) 1.79 (0.83) 1.78 (0.73) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) (SD) Probability of 15.7 12.1 12.6 9.2 – – – – superiority, % Probability of 84.3 87.9 87.4 90.8 – – – – harm, % Probability 7.1 4.4 5.3 3.3 – – – – of > 20% reduc- tion in odds of</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_3.html",
    "associated_text": [
      "By day 90, 78 (15%) of 521 patients assigned to hydrocor tisone and 12 (9.8%) of 122 patients assigned to control had died (Fig. 2). The median adjusted OR for the effect of hydrocortisone, relative to control, on 90 day mortal",
      "ity, estimated from the primary model (which generates"
    ]
  },
  {
    "element_id": "587c58384315e5acf52604d5d60d2c93",
    "page_number": 9,
    "caption": "Table 2 Primary outcome and sensitivity analyses in the full dataset",
    "table_text": "Probability 7.1 4.4 5.3 3.3 – – – – of > 20% reduc- tion in odds of death, % Independent treatment effects for each stratum (no borrowing) using the full model Median adjusted 1.21 (0.19–8.96) 1.46 (0.63–3.70) 1.53 (0.23–11.69) 1.82 (0.72–5.18) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) OR (95% CrI) Mean adjusted OR 2.05 (2.81) 1.65 (0.83) 2.63 (3.78) 2.12 (1.23) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) (SD) Probability of 42.3 19.6 33.4 10.4 – – – – superiority, % Probability of 57.7 80.4 66.6 89.6 – – – – harm, % Probability 35.2 9.8 27.2 5 – – – – of > 20% reduc- tion in odds of death, % Median adjusted 1.56 (0.80–3.31) 1 (Reference) OR (95% CrI) Mean adjusted OR 1.69 (0.65) 1 (Reference) (SD) Probability of 10 – superiority, % Probability of 90 – harm, % Probability 3.4 – of > 20% reduc- tion in odds of death, % Median adjusted 1.49 (0.69–3.68) 1.48 (0.73–3.57) 1.45 (0.70–3.65) 1.48 (0.73–3.50) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)",
    "table_html": "<pre>Probability 7.1 4.4 5.3 3.3 – – – – of > 20% reduc- tion in odds of death, % Independent treatment effects for each stratum (no borrowing) using the full model Median adjusted 1.21 (0.19–8.96) 1.46 (0.63–3.70) 1.53 (0.23–11.69) 1.82 (0.72–5.18) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) OR (95% CrI) Mean adjusted OR 2.05 (2.81) 1.65 (0.83) 2.63 (3.78) 2.12 (1.23) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) (SD) Probability of 42.3 19.6 33.4 10.4 – – – – superiority, % Probability of 57.7 80.4 66.6 89.6 – – – – harm, % Probability 35.2 9.8 27.2 5 – – – – of > 20% reduc- tion in odds of death, % Median adjusted 1.56 (0.80–3.31) 1 (Reference) OR (95% CrI) Mean adjusted OR 1.69 (0.65) 1 (Reference) (SD) Probability of 10 – superiority, % Probability of 90 – harm, % Probability 3.4 – of > 20% reduc- tion in odds of death, % Median adjusted 1.49 (0.69–3.68) 1.48 (0.73–3.57) 1.45 (0.70–3.65) 1.48 (0.73–3.50) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_4.html",
    "associated_text": [
      "ity, estimated from the primary model (which generates",
      "7.1",
      "Probability",
      "3.3"
    ]
  },
  {
    "element_id": "41955ae83595c84a076279cbd7c4f1d8",
    "page_number": 9,
    "caption": "No caption",
    "table_text": "1.49 (0.69–3.68) 1.48 (0.73–3.57) 1.45 (0.70–3.65) OR (95% CrI) 1.69 (0.76) 1.68 (0.73) 1.67 (0.76) 1.67 (0.73) (SD) 13.8 12.0 13.9 12.3 – – – – superiority, % 86.2 88.0 86.1 87.7 – – – – harm, %",
    "table_html": "<pre>1.49 (0.69–3.68) 1.48 (0.73–3.57) 1.45 (0.70–3.65) OR (95% CrI) 1.69 (0.76) 1.68 (0.73) 1.67 (0.76) 1.67 (0.73) (SD) 13.8 12.0 13.9 12.3 – – – – superiority, % 86.2 88.0 86.1 87.7 – – – – harm, %</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_5.html",
    "associated_text": [
      "Sensitivity analyses",
      "Pooled treatment effect across strata using the full model",
      "Analyses restricted to patients randomized to either fixed duration hydrocortisone or control",
      "1.49 (0.69 3.68) 1.48 (0.73 3.57) 1.45 (0.70 3.65)",
      "1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)",
      "Mean adjusted OR",
      "Probability of"
    ]
  },
  {
    "element_id": "7d0c08660f93230f81c40a9dea67717b",
    "page_number": 10,
    "caption": "Table 2 (continued)",
    "table_text": "90-day mortality Hydrocortisone (n = 536) Control (n = 122) Probability 6.5 5.4 6.6 5.2 – – – – of > 20% reduc- tion in odds of",
    "table_html": "<pre>90-day mortality Hydrocortisone (n = 536) Control (n = 122) Probability 6.5 5.4 6.6 5.2 – – – – of > 20% reduc- tion in odds of</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_6.html",
    "associated_text": [
      "death, %",
      "The model adjusts for age, sex, site (nested within country), domain ineligibility, randomization within each domain, strata (vasopressor dependent shock versus no vasopressor dependent shock and influenza versus no influenza), disease state (not on invasive mechanical ventilation, ventilated but not severely hypoxic, or ventilated and severely hypoxic) and time epochs. Odds ratios (OR) < 1 indicate improved outcomes. Probability of harm (OR > 1) is the inverse of probability of superiority (OR < 1)",
      "SD denotes standard deviation, CrI denotes credible interval",
      "OR for each stratum with fixed borrowing) was 1.52 (95% CrI, 0.69 to 3.56) for vasopressor dependent shock due to influenza; 1.53 (0.76 to 3.29) for vasopressor dependent shock not due to influenza; 1.62 (0.73 to 3.84) for influ enza without vasopressor dependent shock, and; 1.63 (0.80 to 3.59) for severe CAP with neither influenza nor vasopressor dependent shock. These OR yielded poste rior probabilities of > 20% reduction in the odds of death at 90 days of 7.1%, 4.4%, 5.3%, and 3.3%, respectively. Probabilities of superiority (OR < 1) were 15.7%, 12.1%, 12.6%, and 9.2%, respectively, with corresponding prob abilities of harm (OR > 1) 84.3%, 87.9%, 87.4%, and 90.8%,"
    ]
  },
  {
    "element_id": "4a08fbfaaa6463115de54644e29e338d",
    "page_number": 11,
    "caption": "No caption",
    "table_text": "Hydrocortisone (n = 536) Control (n = 122) Hydrocortisone (n = 339) Control (n = 116) ICU mortality # Patients with known outcome 535 122 338 116 Deaths, n (%) 50 (9.3) 7 (5.7) 42 (12.4) 7 (6) Median adjusted OR (95% CrI) 1.49 (0.62–4.18) 1 (Reference) 1.73 (0.65–5.07) 1 (Reference) Mean adjusted OR (SD) 1.73 (0.97) 1 (Reference) 2.00 (1.19) 1 (Reference) Probability of superiority, % 19.3 – 13.6 – Probability of harm, % 80.7 – 86.4 – Probability of > 20% reduction in odds of death, % 10.1 – 7.1 – ICU Length of stay (LOS) # Patients with known outcome 535 122 339 116 LOS (days) median (10th to 90th percentile) 5 (1–43) 5.5 (2–34) 5 (1 to –) 5.5 (2–37) Median adjusted HR (95% CrI) 1.05 (0.84–1.31) 1 (Reference) 1.04 (0.81–1.35) 1 (Reference) Mean adjusted HR (SD) 1.06 (0.12) 1 (Reference) 1.05 (0.13) 1 (Reference) Probability of superiority, % 32.3 – 38.9 – Probability of harm, % 67.7 – 61.1 – Probability of > 20% reduction in LOS, % 2.2 – 4.4 – Ventilator-free days (VFD) # Patients with known outcome 535 122 338 116 VFD (days) median (IQR) 27 (19–28) 28 (19–28) 26 (17–28) 28 (18.75–28) Median adjusted OR (95% CrI) 0.85 (0.60 to 1.41) 1 (Reference) 0.85 (0.58 to 1.43) 1 (Reference) Mean adjusted OR (SD) 0.89 (0.22) 1 (Reference) 0.92 (0.21) 1 (Reference) Probability of superiority, % 72.8 – 72.3 – Probability of harm, % 27.3 – 27.7 – Probability of > 20% improvement in odds of VFD, % 47.6 – 70.9 – Organ support-free days (OSFD) # Patients with known outcome 535 122 338 116 OSFD (days) median (IQR) 24 (16–26) 22.5 (15–26) 24 (13.25–26) 22 (15–26) Median adjusted OR (95% CrI) 0.82 (0.56–1.22) 1 (Reference) 0.83 (0.53–1.13) 1 (Reference) Mean adjusted OR (SD) 0.83 (0.16) 1 (Reference) 0.82 (0.16) 1 (Reference) Probability of superiority, % 85.4 – 91.3 – Probability of harm, % 14.6 – 8.7 – Probability of > 20% improvement in odds of OSFD, 54.9 – 49.4 – % Hospital Length of stay (LOS) # Patients with known outcome 536 122 339 116 LOS (days) median (10th to 90th percentile) 12 (4 to –) 14 (4–55) 12 (4 to –) 14 (3–58) Median adjusted HR (95% CrI) 1.07 (0.85 to 1.34) 1 (Reference) 1.03 (0.80 to 1.31) 1 (Reference) Mean adjusted HR (SD) 1.07 (0.13) 1 (Reference) 1.03 (0.13) 1 (Reference) Probability of superiority, % 29.7 – 42.4 – Probability of harm, % 70.3 – 57.6 – Probability of > 20% reduction in LOS, % 1.9 – 5.4 – Progression to intubation, ECMO, or death, n/total 64/323 (19.8) 16/76 (21.1) 41/200 (20.5) 15/72 (20.8) (%)",
    "table_html": "<pre>Hydrocortisone (n = 536) Control (n = 122) Hydrocortisone (n = 339) Control (n = 116) ICU mortality # Patients with known outcome 535 122 338 116 Deaths, n (%) 50 (9.3) 7 (5.7) 42 (12.4) 7 (6) Median adjusted OR (95% CrI) 1.49 (0.62–4.18) 1 (Reference) 1.73 (0.65–5.07) 1 (Reference) Mean adjusted OR (SD) 1.73 (0.97) 1 (Reference) 2.00 (1.19) 1 (Reference) Probability of superiority, % 19.3 – 13.6 – Probability of harm, % 80.7 – 86.4 – Probability of > 20% reduction in odds of death, % 10.1 – 7.1 – ICU Length of stay (LOS) # Patients with known outcome 535 122 339 116 LOS (days) median (10th to 90th percentile) 5 (1–43) 5.5 (2–34) 5 (1 to –) 5.5 (2–37) Median adjusted HR (95% CrI) 1.05 (0.84–1.31) 1 (Reference) 1.04 (0.81–1.35) 1 (Reference) Mean adjusted HR (SD) 1.06 (0.12) 1 (Reference) 1.05 (0.13) 1 (Reference) Probability of superiority, % 32.3 – 38.9 – Probability of harm, % 67.7 – 61.1 – Probability of > 20% reduction in LOS, % 2.2 – 4.4 – Ventilator-free days (VFD) # Patients with known outcome 535 122 338 116 VFD (days) median (IQR) 27 (19–28) 28 (19–28) 26 (17–28) 28 (18.75–28) Median adjusted OR (95% CrI) 0.85 (0.60 to 1.41) 1 (Reference) 0.85 (0.58 to 1.43) 1 (Reference) Mean adjusted OR (SD) 0.89 (0.22) 1 (Reference) 0.92 (0.21) 1 (Reference) Probability of superiority, % 72.8 – 72.3 – Probability of harm, % 27.3 – 27.7 – Probability of > 20% improvement in odds of VFD, % 47.6 – 70.9 – Organ support-free days (OSFD) # Patients with known outcome 535 122 338 116 OSFD (days) median (IQR) 24 (16–26) 22.5 (15–26) 24 (13.25–26) 22 (15–26) Median adjusted OR (95% CrI) 0.82 (0.56–1.22) 1 (Reference) 0.83 (0.53–1.13) 1 (Reference) Mean adjusted OR (SD) 0.83 (0.16) 1 (Reference) 0.82 (0.16) 1 (Reference) Probability of superiority, % 85.4 – 91.3 – Probability of harm, % 14.6 – 8.7 – Probability of > 20% improvement in odds of OSFD, 54.9 – 49.4 – % Hospital Length of stay (LOS) # Patients with known outcome 536 122 339 116 LOS (days) median (10th to 90th percentile) 12 (4 to –) 14 (4–55) 12 (4 to –) 14 (3–58) Median adjusted HR (95% CrI) 1.07 (0.85 to 1.34) 1 (Reference) 1.03 (0.80 to 1.31) 1 (Reference) Mean adjusted HR (SD) 1.07 (0.13) 1 (Reference) 1.03 (0.13) 1 (Reference) Probability of superiority, % 29.7 – 42.4 – Probability of harm, % 70.3 – 57.6 – Probability of > 20% reduction in LOS, % 1.9 – 5.4 – Progression to intubation, ECMO, or death, n/total 64/323 (19.8) 16/76 (21.1) 41/200 (20.5) 15/72 (20.8) (%)</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_7.html",
    "associated_text": [
      "All patients randomized to hydrocortisone",
      "Subset randomized at sites offering hydro",
      "or control",
      "cortisone and control",
      "Tracheostomy rate in intubated patients, n/total (%)",
      "22/210 (10.5)",
      "6/46 (13)",
      "14/137 (10.2)"
    ]
  },
  {
    "element_id": "1be7c2c5d23aa2d2168299d78585c545",
    "page_number": 12,
    "caption": "Table 3 (continued)",
    "table_text": "All patients randomized to hydrocortisone Subset randomized at sites offering hydro- or control cortisone and control Rehabilitation hospital 38/534 (7.1) 7 (5.7) 22/337 (6.5) 7 (6) Transfer to another acute hospital 33/534 (6.2) 12 (9.8) 21/337 (6.2) 11 (9.5) ICU readmission*, n/total (%) 19 (3.5) 5 (4.1) 13/339 (3.8) 4 (3.4) Serious adverse events, n/total (%) 7 (1.3) 1 (0.8) 3/339 (0.9) 1 (0.9) 90-day mortality in patients with no baseline mechanical ventilation # Patients with known outcome/total # 314/323 76/76 195/200 72/72 Deaths, n (%) 34 (10.8) 5 (6.6) 24 (12.3) 5 (6.9) Median adjusted OR (95% CrI) 1.36 (0.47–4.68) 1 (Reference) 1.24 (0.40–4.28) 1 (Reference) Mean adjusted OR (SD) 1.67 (1.21) 1 (Reference) 1.53 (1.07) 1 (Reference) Probability of superiority, % 29.2 – 36.7 – Probability of harm, % 70.8 – 63.2 – Probability of > 20% reduction in odds of death, % 81.1 – 25.3 – 90-day mortality in patients with baseline invasive mechanical ventilation # Patients with known outcome/total # 207/213 46/46 136/139 44/44 Deaths, n (%) 44 (21.3) 7 (15.2) 37 (27.2) 7 (15.9) Median adjusted OR (95% CrI) 1.85 (0.67–5.61) 1 (Reference) 2.05 (0.70–6.31) 1 (Reference) Mean adjusted OR (SD) 2.18 (1.37) 1 (Reference) 2.41 (1.49) 1 (Reference) Probability of superiority, % 12.8 – 9.7 – Probability of harm, % 87.2 – 90.3 – Probability of > 20% reduction in odds of death, % 93.3 – 5.0 –",
    "table_html": "<pre>All patients randomized to hydrocortisone Subset randomized at sites offering hydro- or control cortisone and control Rehabilitation hospital 38/534 (7.1) 7 (5.7) 22/337 (6.5) 7 (6) Transfer to another acute hospital 33/534 (6.2) 12 (9.8) 21/337 (6.2) 11 (9.5) ICU readmission*, n/total (%) 19 (3.5) 5 (4.1) 13/339 (3.8) 4 (3.4) Serious adverse events, n/total (%) 7 (1.3) 1 (0.8) 3/339 (0.9) 1 (0.9) 90-day mortality in patients with no baseline mechanical ventilation # Patients with known outcome/total # 314/323 76/76 195/200 72/72 Deaths, n (%) 34 (10.8) 5 (6.6) 24 (12.3) 5 (6.9) Median adjusted OR (95% CrI) 1.36 (0.47–4.68) 1 (Reference) 1.24 (0.40–4.28) 1 (Reference) Mean adjusted OR (SD) 1.67 (1.21) 1 (Reference) 1.53 (1.07) 1 (Reference) Probability of superiority, % 29.2 – 36.7 – Probability of harm, % 70.8 – 63.2 – Probability of > 20% reduction in odds of death, % 81.1 – 25.3 – 90-day mortality in patients with baseline invasive mechanical ventilation # Patients with known outcome/total # 207/213 46/46 136/139 44/44 Deaths, n (%) 44 (21.3) 7 (15.2) 37 (27.2) 7 (15.9) Median adjusted OR (95% CrI) 1.85 (0.67–5.61) 1 (Reference) 2.05 (0.70–6.31) 1 (Reference) Mean adjusted OR (SD) 2.18 (1.37) 1 (Reference) 2.41 (1.49) 1 (Reference) Probability of superiority, % 12.8 – 9.7 – Probability of harm, % 87.2 – 90.3 – Probability of > 20% reduction in odds of death, % 93.3 – 5.0 –</pre>",
    "table_html_file": "files/extracted/tables/hydrocortisone_table_8.html",
    "associated_text": [
      "Hydrocortisone (n = 536) Control (n = 122) Hydrocortisone (n = 339) Control (n = 116)",
      "Within the control arm, six patients were randomized in sites offering shock dependent hydrocortisone but not fixed duration hydrocortisone. The model adjusts for age, sex, site (nested within country), domain ineligibility, randomization within each domain, strata (vasopressor dependent shock versus no vasopressor dependent shock and influenza versus no influenza), disease state (not on invasive mechanical ventilation, ventilated but not severely hypoxic, or ventilated and severely hypoxic) and time epochs. Odds ratios < 1 indicate improved outcomes. Probability of harm (OR > 1) is the inverse of probability of superiority (OR < 1)",
      "OR denotes odds ratio, HR denotes hazard ratio, CrI denotes credible interval, ECMO denotes extracorporeal membrane oxygenation, IQR denotes interquartile range, ICU denotes intensive care unit",
      "During index hospitalization"
    ]
  }
]